Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030

Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030

The Anti-Mullerian Hormone Test Market size was estimated at USD 274.26 million in 2023 and expected to reach USD 305.41 million in 2024, at a CAGR 11.46% to reach USD 586.48 million by 2030.

Anti-Mullerian hormone (AMH) tests are diagnostic tools used to measure the levels of anti-Mullerian hormone, a protein hormone produced by granulosa cells in ovarian follicles. The AMH test provides details about the women's ovarian reserve and estimates the remaining quantity of eggs and potential fertility. In reproductive medicine, these tests are used to assess conditions such as polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (POI). Moreover, AMH tests are used in vitro fertilization (IVF) for medication dosing and predicting ovarian response to stimulation. The rising awareness and incidence of reproductive health issues, the growing need for early and accurate diagnosis of fertility and ovarian health, and the increasing age of first-time pregnancies across the world necessitate fertility assessments, which are accomplished by using AMH testing. In addition, advancements in diagnostic technologies and the expansion of healthcare infrastructure globally increase the accessibility and affordability of these tests. However, limited awareness of AMH tests in low-resource settings hinders their penetration. Moreover, the high cost of these tests and the need for standardized testing protocols across different regions can further complicate their access and consistent adoption in healthcare outcomes. Technological integration to interpret AMH levels and related fertility factors is expected to present a significant opportunity for the growth of the AMH test market.

Regional Insights

Asia-Pacific is exhibiting a rapid increase in awareness and need for reproductive health services, including the anti-Mullerian hormone (AMH) test, primarily attributed to the growing healthcare expenditures and a notable shift in consumer behavior toward preventive healthcare measures. The higher incidence of polycystic ovary syndrome (PCOS) and infertility issues among women and the evolving healthcare system have supported the need for AMH test procedures. In the Americas, the anti-Mullerian hormone test market is driven by advanced healthcare infrastructure, high awareness levels regarding reproductive health, and substantial investment in research and development. Consumer behavior in the region is characterized by a proactive approach to fertility testing, where individuals are inclined toward early diagnosis and treatment. Europe, the Middle East, and Africa represent a highly diverse market for the AMH test, with varying degrees of adoption across the region. Western European countries feature high consumer awareness and a well-established healthcare system supporting reproductive health services. However, Eastern European nations are gradually emerging, propelled by enhancing healthcare infrastructures and policies. The Middle East exhibits a burgeoning healthcare sector, where countries invest heavily in medical tourism, including fertility services. Africa is at a nascent stage and is showing promise with increasing private and public sector initiatives aimed at enhancing women's healthcare services, including fertility testing.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Anti-Mullerian Hormone Test Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of polycystic ovary syndrome worldwide
    • Growing number of IVF and egg-freezing procedures
    • Market Restraints
      • Limited reimbursements available for AMH tests
      • Market Opportunities
        • Advancements in anti-Mullerian hormone test technology
        • Government initiatives for creating awareness associated with reproductive and infertility treatment health
        • Market Challenges
          • Inconsistencies and false results associated with anti-Mullerian hormone kits
          • Market Segmentation Analysis
            • Product: Increasing consumer preference for POC testing to obtain professional oversight
            • End-User: Rising penetration of AMH test kits in commercial labs for accurate and rapid results
            • Distribution: Emerging availability of AMH testing kits on online channels
            • Use: Significant usage of AMH testing kits for human applications
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Anti-Mullerian Hormone Test Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Anti-Mullerian Hormone Test Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Introduction of Novel Assay by Siemens Healthineers' for Assessing Ovarian Reserve
              
              Siemens Healthineers introduced an anti-Mullerian hormone (AMH) assay, a significant development for laboratories specializing in reproductive endocrinology, offering a fast and reliable method for evaluating a woman's ovarian reserve. This test is instrumental for physicians in determining the feasibility of commencing in vitro fertilization (IVF) treatments. The new product launch emphasized the importance of ovarian reserve knowledge in empowering patients and doctors to make informed decisions about IVF, facilitating a more efficient and patient-centric approach to overcome fertility challenges.
              
              The Introduction of MenoCheck by ARUP Laboratories to Revolutionizing Menopausal Management
              
              ARUP Laboratories advanced the management of menopause through the introduction of MenoCheck, a breakthrough immunoassay developed by Ansh Labs. This clinically validated and FDA-cleared test represents a major step forward in accurately determining menopausal status, using the detection of ultralow concentrations of anti-Mullerian hormone (AMH) as a reliable indicator of ovarian reserve.
              
              The Advent of the Elecsys Anti-Müllerian Hormone Plus immunoassay for Enhanced Accessibility and Early Detection
              
              Roche Diagnostics achieved a significant milestone with the CE mark approval for a claim extension to the Elecsys anti-Mullerian hormone (AMH) Plus immunoassay, enabling this blood test as a viable alternative for diagnosing polycystic ovary syndrome (PCOS), representing a departure from the traditional transvaginal ultrasound method. This breakthrough paves the way for earlier and comfortable diagnostic experiences, ultimately fostering targeted therapeutic interventions and lifestyle adjustments to mitigate PCOS's reproductive, metabolic, and psychological impacts.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Anti-Mullerian Hormone Test Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Anti-Mullerian Hormone Test Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Abcam PLC, Ansh Labs LLC, Athenese-Dx, Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMérieux S.A., BioVendor – Laboratorni Medicina A.S., Chengdu VACURE Biotechnology Co., Ltd., CTK Biotech, Inc., Cusabio Technology LLC, Eagle Biosciences, Inc., Elabscience Bionovation Inc., Epitope Diagnostics, Inc., F. Hoffmann-La Roche Ltd., Fujirebio Europe N.V. by H.U. Group Holdings, Inc., Goldsite Diagnostics Inc., Healthy Human Labs Limited (Vitall), Kamiya Biomedical Company, LifeSpan BioSciences, Inc., London Gynaecology Limited, Meridian Bioscience, Inc., Monobind Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tosoh Corporation, and Vitrosens Biotechnology Co., Ltd..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Anti-Mullerian Hormone Test Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Product
              • POC Testing
              • Self-check Kits
              • End-User
                • Commercial Labs
                • Research & development
                • Distribution
                  • Offline Channels
                  • Online Channels
                  • Use
                    • Human
                    • Non-Human Primate
                    • Region
                      • Americas
                        • Argentina
                        • Brazil
                        • Canada
                        • Mexico
                        • United States
                          • California
                          • Florida
                          • Illinois
                          • New York
                          • Ohio
                          • Pennsylvania
                          • Texas
                          • Asia-Pacific
                            • Australia
                            • China
                            • India
                            • Indonesia
                            • Japan
                            • Malaysia
                            • Philippines
                            • Singapore
                            • South Korea
                            • Taiwan
                            • Thailand
                            • Vietnam
                            • Europe, Middle East & Africa
                              • Denmark
                              • Egypt
                              • Finland
                              • France
                              • Germany
                              • Israel
                              • Italy
                              • Netherlands
                              • Nigeria
                              • Norway
                              • Poland
                              • Qatar
                              • Russia
                              • Saudi Arabia
                              • South Africa
                              • Spain
                              • Sweden
                              • Switzerland
                              • Turkey
                              • United Arab Emirates
                              • United Kingdom
                              
                              
                              Please Note: PDF & Excel + Online Access - 1 Year